Invivyd’s LIBERTY Win Wasn’t Enough to Hold the Rally
VYD2311 looked better tolerated than Comirnaty, but combo stats were mixed. Shorts, profit-taking, and a crowded COVID market weighed on IVVD.
/ 5 items
#IVVD↓
Invivyd Promotes Marc Elia to CEO and Maps Dual Path for VYD2311 Data
Cantor keeps Overweight and a $10 target after the stock drop.
Invivyd Drops Major Update: COVID Study on Track + New Measles Super-Antibody Discovered
Invivyd just announced major progress on its COVID-19 prevention study and a potential first-in-class measles antibody (VMS063).
Jefferies Backs Relmada, BTIG Turns Bullish on Invivyd
Jefferies and BTIG start coverage on Relmada and Invivyd with Buy ratings, citing pipeline shifts, strong assets, and large market potential.
Invivyd Advances VYD2311: New Choice for COVID Protection
Invivyd is developing VYD2311, a non-vaccine antibody, to prevent COVID. Two key trials (DECLARATION/LIBERTY) will test its safety and effectiveness vs. placebo and mRNA vaccines, aiming to offer a flexible new choice for protection.